OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
Top Page
OKYO Pharma Limited Sponsored ADR
(NASDAQ:OKYO)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-1.96% Downside)
Action:ReiteratedDate:02/25/26
The score is primarily held down by weak financial fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) and bearish technicals (below key moving averages with negative MACD). Improved 2025 cost control and a debt-free balance sheet provide only limited offset.
Positive Factors
Regulatory de-risking of pivotal trial
FDA alignment on the Phase 2b/3 design, primary VAS endpoint and CMC approach materially lowers regulatory execution risk. That de-risking improves the durability of the development plan, making the planned pivotal study more likely to meet expectations and shortening regulators-related uncertainty.
Negative Factors
Pre-revenue with persistent net losses
OKYO has no product revenue and recurring net losses, meaning operations are reliant on financing rather than cash generation. This structural lack of commercial cash flow sustains funding dependency and leaves long-term viability contingent on successful trial outcomes and future commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory de-risking of pivotal trial
FDA alignment on the Phase 2b/3 design, primary VAS endpoint and CMC approach materially lowers regulatory execution risk. That de-risking improves the durability of the development plan, making the planned pivotal study more likely to meet expectations and shortening regulators-related uncertainty.
Read all positive factors
OKYO Pharma Limited Sponsored ADR (OKYO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$77.57M
Dividend YieldN/A
Average Volume (3M)131.52K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,370,197
10 Day Avg. Volume47,624
30 Day Avg. Volume131,524
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-9.04
Price to Sales (P/S)0.00
P/FCF Ratio-27.67
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.03K
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$7.00Price Target Upside357.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model
Company Description
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, OKYO Pharma has not been consistently generating revenue from product sales, and specific, recurring commercial revenue streams are not publicly established in the way they are for profitable, markete...
OKYO Pharma Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.17K | -2.56K | -3.87K | -3.80K | -2.42K | -13.09K |
| EBITDA | -9.58M | -7.08M | -15.75M | -13.18M | -6.21M | -3.35M |
| Net Income | -4.61M | -4.71M | -16.83M | -13.27M | -5.43M | -3.35M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 3.68M | 1.54M | 5.20M | 4.30M | 7.09M |
| Cash, Cash Equivalents and Short-Term Investments | 4.22M | 1.56M | 826.85K | 4.05M | 2.70M | 6.89M |
| Total Debt | 185.79K | 0.00 | 0.00 | 2.22M | 0.00 | 98.76K |
| Total Liabilities | 8.06M | 9.23M | 7.42M | 7.26M | 1.35M | 1.77M |
| Stockholders Equity | -3.42M | -5.55M | -5.88M | -2.05M | 2.95M | 5.32M |
Cash Flow | ||||||
| Free Cash Flow | -3.10M | -1.81M | -9.49M | -7.70M | -5.47M | -1.61M |
| Operating Cash Flow | -3.10M | -1.81M | -9.49M | -7.70M | -5.47M | -1.60M |
| Investing Cash Flow | -1.21K | -1.21K | 0.00 | -5.92K | -1.67K | -18.11K |
| Financing Cash Flow | 6.42M | 2.66M | 6.21M | 9.32M | 2.15M | 7.83M |
OKYO Pharma Limited Sponsored ADR Technical Analysis
Negative
1.53
Price Trends
1.73
Negative
1.92
Negative
2.20
Negative
Market Momentum
-0.05
Negative
40.89
Neutral
34.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Negative. The current price of 1.53 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.73, and below the 200-day MA of 2.20, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.89 is Neutral, neither overbought nor oversold. The STOCH value of 34.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OKYO.
OKYO Pharma Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $135.20M | 4.86 | -209.00% | ― | ― | 40.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $536.08M | -4.97 | -83.86% | ― | ― | -19.69% | |
49 Neutral | $59.75M | -1.00 | -71.28% | ― | -10.03% | 11.06% | |
45 Neutral | $178.37M | -1.27 | -97.41% | ― | ― | -60.99% | |
42 Neutral | $77.57M | -7.23 | ― | ― | ― | ― |
* Healthcare Sector Average
OKYO
OKYO Pharma Limited Sponsored ADR
1.53
0.41
36.61%
BMEA
Biomea Fusion
1.88
0.15
8.67%
ABOS
Acumen Pharmaceuticals
2.51
1.46
139.05%
TCRX
TScan Therapeutics
1.02
-0.28
-21.54%
ZURA
Zura Bio
5.68
4.54
398.25%
OKYO Pharma Limited Sponsored ADR Corporate Events
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting
Apr 7, 2026
On April 7, 2026, OKYO Pharma announced it will convene a key Scientific Advisory Board meeting with leading ophthalmology experts during the 2026 American Society of Cataract and Refractive Surgery Annual Meeting in Washington, D.C. The board wil...
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
Mar 19, 2026
On March 19, 2026, OKYO Pharma announced that Panetta Partners Limited, an entity in which Executive Chairman and founder Gabriele Cerrone has a beneficial interest, acquired 10,119 of the company’s ordinary shares on Nasdaq at $1.59, increa...
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
Mar 19, 2026
On March 19, 2026, OKYO Pharma announced that non-executive director John Brancaccio acquired 5,000 of the company’s ordinary shares on Nasdaq at $1.61 per share. Following this purchase, Brancaccio’s total holding increased to 31,201 ...
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
Mar 19, 2026
On March 19, 2026, OKYO Pharma disclosed that Chief Development Officer and Director Gary Jacob acquired 30,980 of the company’s ordinary shares on Nasdaq at $1.59, increasing his total holding to 108,920 shares. The insider purchase, coming...
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
Mar 12, 2026
OKYO Pharma Ltd has expanded a previously announced U.S. underwritten equity offering that originally closed on February 17, 2026, in which it sold 10,815,000 ordinary shares at $1.85 per share. On March 12, 2026, underwriter Piper Sandler Co. pa...
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
Feb 23, 2026
On February 23, 2026, OKYO Pharma announced that an abstract detailing the first-in-human study of its lead candidate urcosimod in neuropathic corneal pain has been accepted for presentation at the ARVO 2026 Annual Meeting in Denver, to be held Ma...
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
Feb 13, 2026
On February 12, 2026, OKYO Pharma Limited signed an underwriting agreement with Piper Sandler Co. for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, with a 30-day option for underwriters to purchase up to 1,622,...
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
Feb 13, 2026
On February 12, 2026, OKYO Pharma announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, expected to raise about $20 million in gross proceeds. The company also granted the underwriter a 30-day o...
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
Feb 12, 2026
On February 12, 2026, OKYO Pharma announced plans for an underwritten public offering of its ordinary shares, with all shares to be issued and sold by the company. The company also expects to grant the underwriter a 30-day option to buy up to an a...
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
Feb 11, 2026
On February 11, 2026, OKYO Pharma announced it has shifted its At-The-Market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities Inc. Leerink, a healthcare-focused investment bank, will act as...
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
Feb 11, 2026
On February 10, 2026, OKYO Pharma Ltd entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program allowing the company to sell up to $50 million of its ordinary shares from time to time on Nasdaq or other ...
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
Feb 10, 2026
OKYO Pharma announced on February 10, 2026, that it has appointed Flavio Mantelli, MD, PhD, as Chief Medical Officer, adding a prominent ophthalmology specialist with deep expertise in corneal and ocular surface diseases. Mantelli previously led t...
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
Jan 30, 2026
On January 30, 2026, OKYO Pharma reported interim results for the six months ended September 30, 2025, highlighting a series of clinical, regulatory and financial milestones that advance its lead drug urcosimod for neuropathic corneal pain. Over t...
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
Jan 30, 2026
On January 30, 2026, OKYO Pharma announced that Phase 2 proof-of-concept efficacy and safety data for its lead candidate urcosimod in neuropathic corneal pain have been accepted for presentation at the 2026 American Society of Cataract and Refract...
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
Jan 28, 2026
On January 28, 2026, OKYO Pharma announced it had held a successful Type C meeting with the U.S. Food and Drug Administration regarding the planned Phase 2b/3 human clinical trial of urcosimod for neuropathic corneal pain. The FDA confirmed that t...
OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain
Jan 23, 2026
On January 23, 2026, OKYO Pharma announced that the U.S. Food and Drug Administration authorized a single-patient expanded access (compassionate use) Investigational New Drug application for the use of urcosimod (0.05%) in a patient with severe ne...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.